Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Clinical pharmacokinetics - 1 Jan 2007

Wilde Stefan, Jetter Alexander, Rietbrock Stephan, Kasel Dirk, Engert Andreas, Josting Andreas, Klimm Beate, Hempel Georg, Reif Stefanie, Jaehde Ulrich, Merkel Ute, Busse Dagmar, Schwab Matthias, Diehl Volker, Fuhr Uwe

Abstract excerpt

BACKGROUND AND OBJECTIVE: The BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) chemotherapy regimen for the treatment of advanced Hodgkin's lymphoma has a superior outcome, but its toxicity (mainly haematotoxicity) is pronounced and highly va...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bleomycin
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Etoposide

Share to Hodgkin Disease

Share to Platelet Count

Share to Prednisone

Share to Vincristine

Source

Identifiers

PMID: 17375983
DOI: 10.2165/00003088-200746040-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17375983-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.PMID 17375983Read ↗

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity Read ↗

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Semantic proximity Read ↗

Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.Semantic proximity Read ↗

Dose calculation of anticancer drugs.Semantic proximity Read ↗

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.Semantic proximity Read ↗

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.Semantic proximity Read ↗

Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.Semantic proximity Read ↗

Effect of Bleomycin Hydrolase Gene Polymorphism on Late Pulmonary Complications of Treatment for Hodgkin Lymphoma.Semantic proximity Read ↗

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.